Biogen Idec is a leader in the therapeutic areas of oncology, neurology, and immunology. Biogen Idec strives to be a pioneer in the research and development of advanced therapies for these disease areas.

Biogen Idec has several products on the market throughout Europe and in the US.

AVONEX^® (Interferon beta –1a) was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of Multiple Sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. AVONEX has an active ingredient called interferon beta-1a. Interferons are naturally occurring proteins and glycoproteins produced by cells in response to biological triggers. They are part of the body's natural defense system. AVONEX is marketed globally, with more than 130,000 patients on therapy in over 90 countries.

MABTHERA^® (Rituximab) called RITUXAN in the US, was approved in the US by the FDA in 1997 for the treatment of indolent and aggressive Non Hodgkin Lymphoma (NHL). In 1998, it was approved in the EU for the treatment of relapsed or refractory indolent NHL and in 2002, in combination with CHOP (Cyclophosphamide, Doxuribicin, Vincristine, Prednison) chemotherapy, for the treatment of aggressive NHL. MABTHERA is also approved in Japan for indolent and aggressive NHL. MABTHERA is the world's first licensed monoclonal antibody therapy for the treatment of non-Hodgin's lymphoma (NHL).  In Europe MABTHERA is marketed by F. Hoffmann-LaRoche.

TYSABRI^® (Natalizumab) was approved both in the US and in Europe in June of 2006. It is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following patient groups:

• Patients with high disease activity despite treatment with a beta-interferon;

or

• Patients with rapidly evolving severe relapsing remitting multiple sclerosis.